Erythrocyte aldose reductase correlates with erectile dysfunction in diabetic patients.
Erectile dysfunction (ED) is a common complication of diabetes mellitus. Erythrocyte aldose reductase (AR) has been implicated in a variety of diabetic complications. The subjects were 62 diabetic patients, of whom 25 were treated with hemodialysis (chronic renal failure CRF group) and the remaining 37 did not have chronic renal failure (DM group). The controls were 20 healthy volunteers age-matched to the patients. The level of AR was measured by the quantitative determination kit for AR in all patients and controls. In this study, ED was diagnosed by 5-item version of the International Index of Erectile Function (IIEF-5). The average level of AR in the CRF group was significantly higher than that in the DM group and controls (P<0.001). The average level of AR in the DM group without ED was significantly lower than that in the DM group with ED and controls (P<0.005). These results suggest that the level of AR may be a useful modality for prediction of ED in diabetic patients.
Naya
Y
Y
Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Soh
J
J
Ochiai
A
A
Mizutani
Y
Y
Kawauchi
A
A
Fujito
A
A
Ushijima
S
S
Ono
T
T
Iwamoto
N
N
Aoki
T
T
Imada
N
N
Nakamura
N
N
Yabe-Nishimura
C
C
Miki
T
T
D000368:Aged; D000449:Aldehyde Reductase / Q000378:metabolism*; D015415:Biomarkers; D003928:Diabetic Nephropathies / Q000150:complications*; D007172:Erectile Dysfunction / Q000150:complications / Q000175:diagnosis* / Q000201:enzymology*; D004912:Erythrocytes / Q000201:enzymology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D011237:Predictive Value of Tests
D015415:Biomarkers; D009569:Nitric Oxide; D000449:Aldehyde Reductase